Literature DB >> 11165006

Phenotypic analysis of mice bearing targeted deletions of 11beta-hydroxysteroid dehydrogenases 1 and 2 genes.

M C Holmes1, Y Kotelevtsev, J J Mullins, J R Seckl.   

Abstract

The glucocorticoid metabolising enzymes, 11beta-hydroxysteroid dehydrogenases (11beta-HSD), play a critical role in determining the availability of glucocorticoids to activate their receptors and hence modulate target gene transcription. There are two isozymes, 11beta-HSD-1 and -2, which act in opposing directions. 11beta-HSD-2 acts as a dehydrogenase, converting active corticosterone (cortisol in humans) to its inactive 11-keto derivative (11-dehydrocorticosterone in rodents and cortisone in humans), whereas 11beta-HSD-1 acts as a reductase, regenerating active glucocorticoids in a tissue-specific manner. Owing to the lack of specific inhibitors of these enzymes, it has been difficult to confirm the roles and determine the importance of these enzymes in vivo. Hence, to address this, we produced transgenic mice with null-mutations in the genes encoding the 11beta-HSD-1 or 11beta-HSD-2 enzymes. 11beta-HSD-2 -/- mice show signs of hypertension, hypotonic polyuria, hypokalemia and hypochloremia. These symptoms arise from illicit activation of mineralocorticoid receptors by glucocorticoids, in the absence of the protective action of 11beta-HSD-2. The phenotype is directly comparable to the Syndrome of Apparent Mineralocorticoid Excess, seen in humans with mutations in the 11beta-HSD-2 gene. Mice lacking 11beta-HSD-1, however, show a more subtle phenotype with reduced activation of glucocorticoid-induced processes. They were unable to convert 11-dehydrocorticosterone to corticosterone in vivo, confirming 11beta-HSD-1 as the sole 11-reductase in the mouse. They have elevated circulating levels of plasma corticosterone levels and adrenal hyperplasia, but they also have attenuated glucocorticoid-induced activation of gluconeogenic enzymes in response to fasting, and lower glucose levels in response to obesity or stress. Overall, these transgenic models have proved very useful for elucidating the roles of 11beta-HSDs in vivo and will be a unique resource for investigating the importance of each enzyme in the diverse actions of glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11165006     DOI: 10.1016/s0303-7207(00)00386-5

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  12 in total

1.  Glucocorticoids exert opposing effects on macrophage function dependent on their concentration.

Authors:  Hee-Young Lim; Nora Müller; Marco J Herold; Jens van den Brandt; Holger M Reichardt
Journal:  Immunology       Date:  2007-04-23       Impact factor: 7.397

2.  Antisense reduction of 11β-hydroxysteroid dehydrogenase type 1 enhances energy expenditure and insulin sensitivity independent of food intake in C57BL/6J mice on a Western-type diet.

Authors:  Guoping Li; Antonio Hernandez-Ono; Rosanne M Crooke; Mark J Graham; Henry N Ginsberg
Journal:  Metabolism       Date:  2011-12-29       Impact factor: 8.694

3.  Molecular docking and structural analysis of cofactor-protein interaction between NAD⁺ and 11β-hydroxysteroid dehydrogenase type 2.

Authors:  Hideaki Yamaguchi; Tatsuo Akitaya; Tao Yu; Yumi Kidachi; Katsuyoshi Kamiie; Toshiro Noshita; Hironori Umetsu; Kazuo Ryoyama
Journal:  J Mol Model       Date:  2011-06-11       Impact factor: 1.810

Review 4.  Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.

Authors:  Eliza B Geer; Julie Islam; Christoph Buettner
Journal:  Endocrinol Metab Clin North Am       Date:  2014-03       Impact factor: 4.741

5.  7alpha-hydroxytestosterone affects 1 beta-hydroxysteroid dehydrogenase 1 direction in rat Leydig cells.

Authors:  Guo-Xin Hu; Qing-Quan Lian; Bing-Bing Chen; Pramod V Prasad; Narender Kumar; Zhi-Qiang Zheng; Ren-Shan Ge
Journal:  Endocrinology       Date:  2009-12-16       Impact factor: 4.736

6.  Liver is the site of splanchnic cortisol production in obese nondiabetic humans.

Authors:  Rita Basu; Ananda Basu; Meagan Grudzien; Paul Jung; Peer Jacobson; Michael Johnson; Ravinder Singh; Michael Sarr; Robert A Rizza
Journal:  Diabetes       Date:  2008-10-13       Impact factor: 9.461

7.  Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients.

Authors:  René Baudrand; Cristian A Carvajal; Arnoldo Riquelme; Mauricio Morales; Nancy Solis; Margarita Pizarro; Alex Escalona; Camilo Boza; Gustavo Pérez; Angélica Domínguez; Marco Arrese; Carlos E Fardella
Journal:  Obes Surg       Date:  2009-08-19       Impact factor: 4.129

8.  Epigenetic effects of prenatal stress on 11β-hydroxysteroid dehydrogenase-2 in the placenta and fetal brain.

Authors:  Catherine Jensen Peña; Catherine Monk; Frances A Champagne
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

9.  Hypothalamic-pituitary-adrenal axis abnormalities in response to deletion of 11beta-HSD1 is strain-dependent.

Authors:  R N Carter; J M Paterson; U Tworowska; D J Stenvers; J J Mullins; J R Seckl; M C Holmes
Journal:  J Neuroendocrinol       Date:  2009-07-07       Impact factor: 3.627

10.  Local corticosterone activation by 11β-hydroxysteroid dehydrogenase 1 in keratinocytes: the role in narrow-band UVB-induced dermatitis.

Authors:  Saori Itoi-Ochi; Mika Terao; Hiroyuki Murota; Ichiro Katayama
Journal:  Dermatoendocrinol       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.